Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

SpringerPlus

Table 1 Baseline characteristics

	Mitoxantrone		CMFP
Characteristics	n	%	n	%
Age, years
<50	53	27	63	32
50–59	63	32	48	25
60–69	57	29	65	34
≥70	24	12	17	9
Unknown	0	0	1	<1
Liver or brain metastases	84	43	77	40
Interval from diagnosis of breast cancer to diagnosis of advanced disease ≥2 years	90	46	101	52
ECOG performance status
0	58	29	58	30
1	84	43	82	42
2	38	19	41	21
3	17	9	13	7
Hormone receptor status
ER or PR positive	92	48	77	41
ER and PR negative	38	20	37	20
ER and PR unknown	62	32	73	39
Previous chemotherapy	37	19	35	18
Previous endocrine therapy	167	85	158	81